Contemporary questions about the initial treatment of advanced forms of prostate cancer

So the discussion about how to use the data from the CHAARTED, STAMPEDE, and LATITUDE trials in the initial treatment of men with node-positive and metastatic hormone-sensitive and castration-resistant prostate cancer continues to be an issue of intense discussion among urologic and medical oncologists. … READ MORE …

Chaarting direction after stampeding along the relevant latitude

So about 3 years after the initial report of the results from the CHAARTED trial, 2 years after the initial report from the ADT + docetaxel arm of the STAMPEDE trial, and 3 months after the reports and publication of data from the LATITUDE trial and the ADT + abiraterone arm of the STAMPEDE trial, … READ MORE …

Should you be adding abiraterone acetate to your ADT? — Part II

So one of the benefits of being at the annual ASCO meeting is that you get to talk to lots of medical oncologists who specialize in treating prostate cancer — if you are patient and polite. … READ MORE …

Data from the LATITUDE trial to be presented at ASCO

According to an e-mail your sitemaster has just received from ASCO, we will be getting the initial results from the LATITUDE trial at the upcoming ASCO meeting in June this year. … READ MORE …

Diet, nutrition, place, and risk for prostate cancer

A newly published paper in the journal Nutrients doesn’t tell us anything really new about the likely correlations between nutrition and risk for prostate cancer, but it does offer us some interesting information about the time frame over which such correlations may take effect. … READ MORE …